Study of the effect of benzoic acid on glutamic acid

Not Applicable

Recruiting

• Conditions: Schizophrenia; F03.700

• Registration Number: JPRN-jRCTs031200050
• Lead Sponsor: Iwata Yusuke

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1) DSM-V diagnosis of schizophrenia or schizoaffective disorder.
2) Age 18 to 65 years.
3) History of failure (score of 4 or more on 2 PANSS positive symptom items and CGI-Severity score of 4 or more) to respond to two or more different kinds of antipsychotics, each attaining a chlorpromazine daily dose of 400 mg or more for a duration 4 or more consecutive weeks.
4) On the same antipsychotic in the last 4 weeks before the inclusion.
5) Subject who provided written informed consent for research.

Exclusion Criteria

1) Substance abuse or dependence (within past six months), excluding nicotine and caffeine.
2) Metal implants or a pace-maker that would preclude the MRI scan.
3) History of head trauma resulting in loss of consciousness > 30 minutes that required medical attention.
4) Unstable physical illness or significant neurological disorder including a seizure disorder.
5) Refusal to give consent to investigator to communicate with physician of record for the entire duration of the study.
6) Psychiatric concerns raised by the physician of record regarding participation in the study.
7) Currently taking clozapine
8) Currently taking medications that may directly impact the glutamatergic system (i.e. lamotrigine, topiramate, memantine)

Study & Design

• Study Type: Interventional
• Study Design: Not specified